Orchid in pact with US co for oral non-antibiotic drug

06 May 2010 Evaluate

Orchid Chemicals & Pharmaceuticals has entered into an out-licensing and distribution agreement with the US-based pharma company Alvogen for marketing eight of Orchid's oral non-antibiotic generic formulations in the US market.

 

Orchid will develop and manufacture eight oral non-antibiotic formulations for licensing to and marketing by Alvogen in the US. Alvogen will source these products from Orchid exclusively. The products will be manufactured at Orchid's facilities, which are approved by the USFDA.

 

Alvogen would pay certain dossier licence fees to Orchid based on development and regulatory milestones and share profits arising from marketing of these products in the US with Orchid. Both the companies would share the legal expenses and bio-study costs.

 

These formulations licensed to Alvogen under the agreement comprise products in the high-growth therapeutic segments of CNS and Osteoporosis among others. The combined addressable market size of these products is around $8 billion.

crackcrack

Orchid Pharma Share Price

829.90 7.15 (0.87%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×